Trial · NCT04777201
Adverse events708
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 708
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cataract | Eye disorders | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 56 | 520 | 78 |
| other | Cataract | Eye disorders | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 63 | 505 | 80 |
| other | Cataract | Eye disorders | Substudy: Faricimab PTI | 2 | 113 | 2 |
| other | Neovascular age-related macular degeneration | Eye disorders | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 60 | 520 | 70 |
| other | Neovascular age-related macular degeneration | Eye disorders | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 55 | 505 | 65 |
| other | Neovascular age-related macular degeneration | Eye disorders | Substudy: Faricimab PTI | 2 | 113 | 3 |
| other | Posterior capsule opacification | Eye disorders | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 14 | 520 | 17 |
| other | Posterior capsule opacification | Eye disorders | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 26 | 505 | 30 |
| other | Posterior capsule opacification | Eye disorders | Substudy: Faricimab PTI | 1 | 113 | 1 |
| other | COVID-19 | Infections and infestations | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 61 | 520 | 65 |
| other | COVID-19 | Infections and infestations | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 48 | 505 | 49 |
| other | COVID-19 | Infections and infestations | Substudy: Faricimab PTI | 5 | 113 | 5 |
| serious | Anaemia | Blood and lymphatic system disorders | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 0 | 520 | 0 |
| serious | Anaemia | Blood and lymphatic system disorders | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 1 | 505 | 1 |
| serious | Anaemia | Blood and lymphatic system disorders | Substudy: Faricimab PTI | 1 | 113 | 1 |
| serious | Anaemia vitamin B12 deficiency | Blood and lymphatic system disorders | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 1 | 520 | 1 |
| serious | Anaemia vitamin B12 deficiency | Blood and lymphatic system disorders | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 0 | 505 | 0 |
| serious | Anaemia vitamin B12 deficiency | Blood and lymphatic system disorders | Substudy: Faricimab PTI | 0 | 113 | 0 |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 0 | 520 | 0 |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 1 | 505 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04777201/events